Top Markets
#1 DogBull DogBull +105.03%
#2 ADO Protocol ADO Protocol +63.41%
#3 Siacoin Siacoin +46.50%
#4 MarsCoin MarsCoin +37.49%
#5 Useless Coin Useless Coin +36.09%
#6 Ontology Gas Ontology Gas +27.76%
#7 UnifAI Network UnifAI Network +27.18%
#8 Glidr Glidr +19.86%
#9 Falcon Finance Falcon Finance +17.20%
#10 Apertum Apertum +14.82%
Coin of the day
DogBull DogBull
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Newron Pharmaceuticals S.p.A. Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A.

NP5
Clasificación en acciones #15974
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Precio por acción
$15.42
Capitalización bursátil
$320.83M
Cambio (1 día)
-1.52%
Cambio (1 año)
40.67%
País
IT
Comercio Newron Pharmaceuticals S.p.A. (NP5)

Categoría

Healthcare
Ingresos de Newron Pharmaceuticals S.p.A. (NP5)
Ingresos en Sep 2026 TTM: 0
Según los últimos informes financieros de Newron Pharmaceuticals S.p.A., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Newron Pharmaceuticals S.p.A. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH